Article Text

Download PDFPDF

Neuromuscular and sensory disturbances in patients with well treated coeliac disease
  1. L Luostarinen1,
  2. S-L Himanen2,
  3. M Luostarinen3,
  4. P Collin4,
  5. T Pirttilä5
  1. 1Departments of Neurology, Tampere University Hospital and Medical School, University of Tampere, and Päijät-Häme Central Hospital, Lahti, Finland
  2. 2Department of Clinical Neurophysiology, Tampere University Hospital and Medical School
  3. 3Department of Surgery, Tampere University Hospital and Medical School, University of Tampere, and Päijät-Häme Central Hospital
  4. 4Department of Internal Medicine, Tampere University Hospital and Medical School
  5. 5Departments of Neurology, University of Tampere, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
  1. Correspondence to:
 Dr L Luostarinen, Department of Neurology, Päijät-Häme Central Hospital, Keskussairaalankatu 7, FIN -15850 Lahti, Finland; 


Objectives: A body of evidence shows that coeliac disease is associated with protean manifestations outside the intestine, and neurological disorders are well recognised. However, it remains obscure whether there are signs of clinical or subclinical nervous system involvement even in patients adopting an adequate gluten free diet. The aim of this study was to assess in a controlled study whether patients with treated coeliac disease carry an increased risk for neuropathy and characterise the type of possible neuropathy.

Methods: Electroneuromyographic findings and vibration, thermal, and tactile thresholds of 26 patients with coeliac disease and 23 patients with reflux disease were analysed.

Results: Six (23.1 %) coeliac disease patients and one (4.3 %) reflux disease patient showed findings of chronic axonal neuropathy in quantitative needle EMG. In addition, two coeliac disease patients showed findings suggestive for myopathy. There were no significant differences in warm, cold, or vibration thresholds between the groups but means of heat pain thresholds and tactile thresholds were significantly higher in coeliac patients than in controls.

Conclusion: An increased occurrence of axonal neuropathy was observed in well treated coeliac disease. This further indicates that neurological manifestations occur even in patients without overt malaborption.

  • coeliac disease
  • neuropathy
  • myopathy
  • gluten free diet
  • ENMG, electroneuromyography
  • EMG, electromyography
  • MUP, motor unit potential

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Coeliac disease is an inflammatory condition of the small intestine characterised by villous atrophy and crypt hyperplasia induced by dietary gluten in genetically susceptible people, possibly affecting 1:300–1:100 of the population. The most common symptoms are diarrhoea, weight loss, and malabsorption, which recover with a gluten free diet. Coeliac disease may remain silent, but it can lead to various non-gastrointestinal complications such as osteoporosis, infertility, or lymphoma. Gluten free diet is beneficial in preventing these complications, and the risk seems to be altogether low in treated patients. The diagnosis is established by the finding of small bowel villous atrophy and clinical or histological remission on gluten free diet.1 Untreated coeliac disease may present with various neurological manifestations such as cerebellar ataxia, epilepsy, or brain atrophy.2–6 Association between peripheral neuropathy and coeliac disease has been described,7–9 and recently, Hadjivassiliou with his colleagues reported nine patients in whom neuromuscular disorder was a presenting feature of coeliac disease.9 Diabetes and alcohol misuse are the most common causes of peripheral neuropathy in developed countries. Other well established causes of neuropathy include hereditary, metabolic, toxic, infectious, inflammatory, ischaemic, and paraneoplastic disorders. However, despite extensive evaluation, the aetiology remains unknown in up to 20% of patients with neuropathy even in very specialised neurological units.10,11

The role of gluten free diet has remained unknown in modifying symptoms and findings of neuropathy in coeliac disease. Gluten free diet may reverse or at least slow down the progression of peripheral neuropathy and on the other hand, transgressions in gluten free diet may exacerbate neurological disorders in coeliac disease. In one case report the symptoms disappeared after introducing gluten free diet.8

The aim of this cross sectional study was to assess whether even patients with a well treated coeliac disease carry an increased risk of neuropathy.


The study was carried out at the Department of Neurology in Tampere University Hospital. The study group comprised 26 patients with coeliac disease. The diagnosis of coeliac disease had been established according to current criteria of European Society for Paediatric Gastroenterology and Nutrition12 at the department of Medicine in Tampere University Hospital. All coeliac disease patients were maintaining gluten free diet since the establishment of the diagnosis for a median of three years (range 2–28). They were in clinical and histological remission—that is, they had no small bowel mucosal atrophy anymore. Control biopsies were no older than three years before neurophysiological studies and the strictness of gluten free diet was assessed by interview. Twenty three patients with gastro-oesophageal reflux disease served as controls; coeliac disease was excluded by histological examination of small bowel mucosa while these patients were evaluated for surgical treatment for gastro-oesophageal reflux disease (table 1).

Table 1

Demographic data

The study protocol was approved by the ethical committee of Tampere University Hospital, and written informed consent was obtained from all patients.

Neurophysiological examinations included the measures of the function of both motor fibres and sensory large fibres and small myelinated and unmyelinated fibres.

Electroneuromyography (ENMG) was carried out using a Keypoint (Dantec, Skovlunde, Denmark) ENMG device. As a rule, the ENMG was performed to the left extremities. In addition, the right extremities were examined in patients with predominantly right sided symptoms. Concentric needle electromyography (EMG) was performed on one distal (m tibialis anterior) and one proximal (m biceps brachii) muscle. The EMG was considered abnormal if fibrillation or positive sharp waves, or both were present in more than one location within the muscle. In addition, the muscles were studied quantitatively by the multi-mup analysis method.13 The number of outliers14 were noticed as well as the mean amplitude and duration of the motor unit potentials (MUPs), which were compared with reference values provided by the manufacturer.15 The results were considered abnormal if the number of outliers exceeded three, or the mean values were outside the normal range (>2.5 SD). Nerve conduction studies were carried out in motor nerves (left median, ulnar, and peroneal nerves) and sensory nerves (left median, ulnar, radial, and sural nerves). All studies were performed with surface electrodes using standard techniques16,17 with the exception of the median and ulnar digital nerves, which were measured antidromically. The hands and feet were warmed at least up to 30°C before all conduction velocity measurements. The left peroneal motor conduction measurements, the left sural and radial sensory measurements, and F waves of all motor nerves were utilised. The results were compared with reference values provided by the manufacturer standardised for age and height. The conduction velocities were considered abnormal if they were slower than 2.5 SD from the calculated mean.

Vibration thresholds were measured from carpal and tarsal areas using the method of limits (Vibrameter, Somedic, Stockholm, Sweden). In addition, vibration thresholds from the index fingers and big toes were studied by the Bio-Thesiometer (Bio Medical Instrument, Newbury, OH, USA). Thermal thresholds (heat, cold, and heat pain thresholds) were assessed by a skilled technician by Somedic Thermotest equipment (Somedic) as previously described.18 Tactile thresholds were assessed with Semmes-Weinstein monofilaments19 in dermatomes L3 and S1.

Statistical methods

Data were expressed as means with standard deviations or frequencies as indicated. Confidence intervals (95%) and contingency table with χ2 test and Mann-Whitney U test were used for statistical comparisons when appropriate.


Clinical examination

Nine coeliac disease patients and 11 patients with reflux disease complained of numbness and paraestesias distally in the extremities. Objective clinical signs of polyneuropathy (absent tendon reflexes and diminished sensory findings) were found in three coeliac disease patients. Seven (27%) coeliac disease patients and five (22%) control patients had a possible predisposing factor to neuropathy (table 1); the difference was not statistically significant. Altogether four patients suffered from alcoholism, one had operated breast cancer, two had medically treated hypothyroidism, and two had treated Graves’ disease, one suffered from inactive ankylosing spondylitis and two had treated rheumatoid arthritis. No patients had previous diagnosis of diabetes, vitamin deficiency, or malnutrition.

ENMG findings

Altogether six (23.1%, three with clinically symptomatic and three asymptomatic neuropathy) coeliac disease patients and one (4.3%) reflux disease patient revealed findings of chronic axonal motor neuropathy in quantitative EMG with increased amplitude or duration of the MUPs. The findings were more prominent in distal than proximal muscles in five of six coeliac disease patients. None of the subjects had fibrillations or positive sharp waves in EMG. The clinical data and results of patients with neuropathy are summarised in table 2. All conduction velocities and amplitudes of the action potentials as well as F latencies were within reference values in each coeliac and control patient. In neuropathy patients sensory and motor action potential amplitudes tended to be lower. Thus three coeliac disease patients had clinically symptomatic and three had subclinical, mainly distal chronic axonal neuropathy, whereas only one control patient had subclinical axonal neuropathy. Reasons of subjective numbness and paraestesias in the rest of the patients remained unclear. Two of the six coeliac patients with neuropathy had a predisposing factor for neuropathy (table 2). Four (21.1%) of 19 coeliac disease patients without predisposing factor compared with one (5.6%) out 18 controls had neuropathy findings (p=0.3).

Table 2

Clinical data and neurophysiological findings in seven patients with neuropathy

Two coeliac disease patients (7.7%) showed reduced amplitudes and duration of MUPs in quantitative EMG. Muscle biopsy was not performed because the patients did not show clinical signs of myopathy.

Quantitative somatosensory findings

Heat pain and tactile thresholds in both upper and lower extremities were significantly higher in patients with coeliac disease than in control subjects. There were no significant differences in warm, cold, or vibration thresholds between the groups (table 3). When patients with neuropathy were excluded, mean values of tactile thresholds in both upper and lower extremities and heat pain thresholds in lower extremity were significantly higher in patients with coeliac disease than in control subjects (table 4). All patients with neuropathy finding in ENMG, that is six with coeliac disease and one with reflux disease had higher means of somatosensory thresholds than patients without neuropathy. We could not demonstrate any patient with pure small fibre neuropathy.

Table 3

Quantitative sensory thresholds in patients with coeliac disease and reflux disease

Table 4

Quantitative heat pain and tactile thresholds; patients without neuropathy findings in ENMG


Our study is the largest comparative study assessing the frequency and features of neuromuscular disorders associated with coeliac disease. We showed that even well treated patients with coeliac disease carry an increased risk of neuropathy, to be seen in one fourth (23%) of patients. Even more, 31%, showed abnormalities in neurophysiological studies compared with 4.3% in controls. Although most manifestations were subclinical, coeliac disease can be considered as a risk condition for neuromuscular disorders. In fact, neuropathy in coeliac disease is as common in coeliac disease as in diseases commonly thought to be risk factors for neuropathy. By comparison, in scleroderma, the frequency of neuropathy has been reported to be 34%, clinical neuropathy in 15.6%, and subclinical in 18.8%.20 In patients with newly diagnosed non-insulin dependent diabetes 8.3% had definite or probable polyneuropathy compared with 2.1% among the control subjects; a frequency comparable to our control group.21 Seven patients in the coeliac group and five in the control group had a predisposing factor for neuropathy, of these two coeliac patients had neuropathy (table 2). We cannot exclude that these predisposing conditions might be aetiological factors for neuropathy. However, when people without known predisposing factors for neuropathy were excluded, the frequency of neuropathy was higher (21.1%) in coeliac disease patients than in controls (5.6%). Even though the difference was not statistically significant, the finding suggests that coeliac disease itself may carry an increased risk of neuropathy. On the other hand it may also be that coeliac disease may aggravate neuropathy when there already exists some underlying risk for this complication.

Most studies of neurological complications of coeliac disease have emphasised central nervous system involvement. Association of neuropathy or myopathy with coeliac disease has been described infrequently over time. Holmes22 has analysed neurological manifestations in a community based coeliac disease population (n=388). In this study the frequency of neuropathy was 0.5% and for myopathy 1.3%. In all cases, myopathy was a result of osteomalacia, which is nowadays very uncommon in coeliac disease and responded to treatment with vitamin D and gluten free diet. There are no previous controlled studies with neurophysiological measurements concerning the frequency of neuropathy in association with coeliac disease. Kaplan et al8 described a middle aged man with 15 year history of coeliac disease who developed a large fibre axonopathy affecting mainly sensory fibres. Sural nerve biopsy demonstrated Wallerian degeneration and findings indicating degeneration and regeneration of nerve fibres. One recent study showed inflammatory cell infiltrates in the nerve roots of the spinal cord in a coeliac patient with polyneuropathy.23 The largest series until now was reported by Hadjivassiliou et al.9 They described six patients with axonal sensorimotor polyneuropathy (of whom two presented with a pure motor neuropathy), one patient with mononeuropathy multiplex and one patient with Guillan-Barre type acute polyneuropathy affected by coeliac disease. Sensory deficits were more pronounced than motor findings in six patients with axonal polyneuropathy. Our results verify that polyneuropathy associated with coeliac disease is axonal type and affects both motor and sensory fibres. We also showed for the first time that patients with coeliac disease showed higher heat pain and touch thresholds than controls. This finding still existed when patients with neuropathy diagnosis were excluded from analysis. Increase of heat pain and touch thresholds in coeliac patients compared with controls provide further evidence that peripheral nerve fibres, even small unmyelinated fibres, are affected in coeliac patients.

Even though all our patients were adopting gluten free diet and coeliac disease was in good remission, they still had an increased risk of clinical or subclinical neuropathy. Earlier, patients with coeliac disease were often malnourished and suffered from severe malabsorption of nutrients. Only the most severe cases were detected, and manifest neurological complications occurred in as many as 36% of patients.24 Influence of gluten free diet in the alleviation of the neuropathy is poorly understood. However, polyneuropathy has been reported to resolve after gluten withdrawal in coeliac disease.8 All patients with neuropathy findings were 54 years or older and there may have been long diagnostic delay before introducing gluten free diet. It is therefore not excluded that gluten free diet may have prevented the development of symptomatic neuropathy in some of our patients. Because 23% of our patients on a gluten free diet had still signs of neuropathy, alternative mechanisms, apart from gluten, may be involved in the development of neuropathy.

One possibility for the occurrence of neurological complications in coeliac disease is an immune reaction against a shared epitope expressed in small intestine and peripheral nerve or muscle. Coeliac disease is an inflammatory disorder induced by dietary gluten. Immunological and genetic factors contribute to the pathogenesis of the disease. The genetic susceptibility locus is in the MHC region, and the disease is associated with the HLA-DQ alleles DQA1*0501 and DQB1*0201. A recent study by Hadjivassiliou et al4 has shown the high HLA-DQ 2 association with sporadic ataxia attributable to gluten sensitivity and subsequently confirmed by Burk et al.25 It is probable that immunological factors contribute to the development of neuropathy in coeliac disease.

In conclusion, coeliac patients have an increased frequency of chronic axonal neuropathy, even when adhering to a long term strict gluten free diet. Early detection of coeliac disease might prevent the development of manifest neuropathy. The relation between gluten containing diet and the occurrence of neuropathy is a subject for further studies. Until that, it is reasonable to assume that a strict diet is warranted to prevent manifest neuropathy and follow up of dietary compliance would be indicated.



  • Funding: this work was supported by a grant from the Medical Research Fund of Tampere University Hospital.

  • Competing interests: none declared.